top of page
BVT Survivors.jpg


The Mission of STL Cure Sarcoma is to Generate Funding for Research for All Types of Sarcoma Cancers, both in St. Louis and Nationwide, as well as to Create Awareness About the Disease. We Have Created a Patient-Oriented Event that Celebrates the Life of Survivors/Warriors, Honors the Fight of Loved Ones Lost, and Builds a Community for Those Affected by Sarcoma.


The St. Louis Cure Sarcoma 6K fundraiser was created by a group of individuals directly affected by Sarcoma. We are a group of Sarcoma warriors, survivors, loved ones of those lost, and relatives of those still fighting. Regardless of our different journeys with this disease, we all have one thing in common: We have all been affected by the lack of Sarcoma research and limited treatment options for Sarcoma patients. We created this group with the assistance of our oncologist, Brian Van Tine, M.D., Ph.D., to fund research through our Annual STL Cure Sarcoma 6K Run/Walk. We strongly believe in Dr. Van Tine’s research and have made it a priority to reserve half of the proceeds of this event to benefit his research lab at Washington University in St. Louis. We use the other half of the proceeds to support nationwide Sarcoma research.


Siteman Cancer Center:

The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is an international leader in cancer treatment, research, prevention, education and community outreach. It is the only cancer center in Missouri to hold the prestigious Comprehensive Cancer Center designation from the National Cancer Institute and membership in the National Comprehensive Cancer Network. Parent institutions Barnes-Jewish Hospital and Washington University School of Medicine also are nationally recognized, with U.S. News & World Report magazine consistently ranking both among the best in the country.

Siteman offers the expertise of more than 350 Washington University research scientists and physicians who provide care for nearly 9,000 newly diagnosed cancer patients each year. A full range of advanced diagnostic and treatment services are available for patients with all types of cancer. Siteman also offers patients access to support services throughout their care.

Dr. Brian Van Tine’s Sarcoma Research at Siteman:

We study cancer metabolism using metabolomics to develop novel therapeutic strategies for rare tumors. Sarcomas are group of over 100 types of tumors of mesenchymal origin that can be divided into 2 categories: soft tissue sarcomas and bone sarcomas. We have demonstrated that arginosuccinate synthase 1 (ASS1) is lost in 88% of all sarcomas. This is an exploitable biomarker that correlates with poor prognosis for sarcoma. When ASS1 is not expressed, arginine becomes an essential amino acid that must be delivered by the diet. We are testing whether the ASS1-deficiency of sarcomas may be exploited using the arginine-lowering agent, pegylated arginine deiminase (ADI-PEG20) in vitro and in animal models. By exploiting autophagy induction, we hope to cause cell death using this agent in combination with others. In addition, we have identified other duel metabolic therapies that can be used instead of chemotherapy that also lead to cell death. Finally, we are launching an omics project in angiosarcoma this year to identify new targets for therapy by looking at the metabolome, phosphor-proteome, and DNA and RNA genome of patients.

You can find out more about Siteman Cancer Center on their website:

bottom of page